Eli Lilly and Company
CD226 agonist antibodies
Last updated:
Abstract:
The present invention relates to anti-human CD226 agonist antibodies, which can be useful for treating solid tumor cancers.
Status:
Grant
Type:
Utility
Filling date:
19 Jul 2019
Issue date:
13 Sep 2022